N-Acetylcysteine and Probenecid Adjuvant Therapy for Traumatic Brain Injury

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Medicine

Background:

• Traumatic brain injury (TBI) presents significant therapeutic challenges.
• Many promising neurotherapeutics, like N-Acetylcysteine (NAC), struggle with blood-brain barrier (BBB) penetration and achieving adequate brain concentrations.
• Organic acid-based therapeutics often face efflux challenges from the central nervous system.

Purpose of the Study:

• To explore the potential of combining N-Acetylcysteine (NAC) with probenecid for treating traumatic brain injury (TBI).
• To provide the rationale and background for this combination therapy, supporting further clinical investigation.

Main Methods:

• Utilized probenecid, a known inhibitor of ATP-binding cassette and solute carrier transporters, to block organic acid transport.
• Co-administered probenecid with NAC, a strategy designed to overcome BBB limitations.
• Conducted a proof-of-concept pilot study (Pro-NAC Trial) in children with severe TBI.

Main Results:

• The Pro-NAC Trial (ClinicalTrials.gov NCT01322009) was completed as a proof-of-concept study.
• The combination therapy aims to enhance brain delivery of NAC for TBI treatment.

Conclusions:

• Combination therapy with probenecid and NAC is a logical neurotherapeutic strategy for TBI.
• This approach holds promise for overcoming BBB permeability issues and warrants further clinical investigation for TBI and other CNS diseases.